Home > Healthcare > Biotechnology > Biotechnology R&D > Cell Line Development Market

Cell Line Development Market - By Product (Reagents & Media, Equipment, Accessories & Consumables), By Source (Mammalian, Non-mammalian), By Cell Line (Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line), By Application & Forecast, 2022-2028

  • Report ID: GMI429
  • Published Date: Mar 2022
  • Report Format: PDF

Cell Line Development Market Size

Cell Line Development Market size was valued at around USD 5.8 billion in 2021 and is expected to witness around 10.1% CAGR from 2022 to 2028. Cancer has become more common over the last decade due to changes in food habits, lack of physical activities, and overall lifestyle. Furthermore, technological advancements along with growing vaccine production will increase the demand for cell line development.

cell line development market outlook

Additionally, rising innovations in biologics and increased demand for targeted therapies like monoclonal antibodies will further boost the market. The monoclonal antibodies are widely used in treatment of cancer. The World Health Organization (WHO) declared COVID-19 as a pandemic in March 2020. Since then, the mortality rate due to chronic conditions has increased exponentially. Thus, the impact of COVID-19 on the cell line development industry is observed to be positive. The pandemic called for the need of vaccines in a large scale thus boosting the production requiring cell line development procedures.

Cell line development is a process of developing highly productive, stable cell lines essential for the production and manufacturing of bio-therapeutics. These are single-celled derived and used to produce vaccines, monoclonal antibodies, and fusion proteins. The development process involves screening thousands of clones to find those that yield a high amount of biproduct and exhibit desired critical quality attributes. These properties of cell lines increase their use in the production of biological drug substances. Such scenarios increase the demand for cell line development.

Cell Line Development Market Trends

The increase in the prevalence of cancer in low-income and middle-income countries is one of the major factors driving the cell line development market share. According to the International Agency of Cancer Research, in 2020, 9,503,710 new cancer cases were found in Asia. Aging, global warming, and unhealthy lifestyle lead to physiological changes triggering cancer. The cell line development plays an important role in development of therapeutic monoclonal antibodies and novel-antibody based therapies. Thus, rise in various types of cancer, acceptance of targeted therapies, and technological advancements in cell line development will upsurge the business growth.

Cell Line Development Market Analysis

 cell line development market by product

Based on product, the cell line development market is segmented into reagents and media, equipment, and accessories and consumables. The reagents and media segment accounted for around 53% market share in 2021. These reagents and media are used for culturing of cells. They are essential for the successful production of physiologically relevant cell models for biomedical research and bioproduction. The reagents and media contain sera and supplements that support cell survival, proliferation, and biological function.

Furthermore, the quality of reagents and media affects the experimental results and the production of biotherapeutics. The segmental growth is driven by increasing product approval and new product launches. For instance, in April 2020, CEVEC Pharmaceuticals GmbH announced the launch of the ELEVECTA platform, that will produce stable cell lines for AAV (Adeno-associated viral) vector for gene therapy. The technology increases the production of viral vectors, used in the production of monoclonal antibodies and recombinant proteins.

cell line development market by source

By source, the cell line development market is fragmented into mammalian and non-mammalian cell lines. Among them, the mammalian segment accounted for over USD 4.1 billion in 2021 owing to the frequent use of human cell lines in the expression systems. The mammalian cells undergo post-translational modifications. These modifications are highly exploited in the biomedical research industry.

Furthermore, these mammalian cell lines are also used in the production of monoclonal antibodies. These cell lines can express complex proteins similar to human beings useful in development of biologics and research. These factors demand for cell line development and research. Such advantages of mammalian cell lines will propel the cell line development market growth. Furthermore, enhanced cell engineering, advancements in clone screening techniques and protein expression in mammalian cells will foster the overall market growth.

The cell line development market based on cell line is classified into recombinant cell lines, hybridomas, primary cell lines and continuous cell lines. The recombinant segment is expected to garner over 9.5% CAGR through 2028. A cell line comprising recombinant DNA for the expression of recombinant proteins is known as recombinant cell line. These cell lines are used for toxicity studies and in-vitro testing. This further increases the demand for cell line development.

Furthermore, they are also used in drug discovery programs for assay development. The proteins expressed by recombinant cells are used for screening of target-based identification of compounds. It helps in proper drug screening and development processes.

Additionally, technological advancements in expression vector design along with huge R&D expenditure on development of novel products will further propel the cell line development market growth.

Based on application, the cell line development market is divided into bioproduction, drug discovery, toxicity testing, tissue engineering and research. The bioproduction segment accounted for around USD 2.7 billion in 2021. Increasing R&D expenditure to produce antibiotics, vaccines and other biological substances will accelerate the segmental as well as market growth.

According to WHO, as of January 2022, in total 9 different vaccines have been produced against coronavirus. This rise in production will flourish the market growth. Thus, factors such as increased awareness about vaccination, and production of antibiotics to combat various diseases demand for cell line development.

cell line development market by region

North America cell line development business captured over 34% market share in 2021 and is expected to grow significantly during the forecast years. High regional growth is owing to increased R&D expenditure due to technological developments. These advances are followed by new drug discoveries triggering the adoption of different but unique procedures for bioproduction that will drive the market growth.

According to Congressional Research Service, the U.S. R&D expenditure was USD 656 billion. Out of this, 423 billion were spent on various development processes. Such high R&D expenditure along with continuous technological advancements is expected to propel the cell line development market in the forthcoming years.  Moreover, modernizing the cell line development industry for tissue engineering, drug development, studying gene expression, production of bio-therapeutics will further upsurge the cell line development growth.

Cell Line Development Market Share

Some of the key players operating in the cell line development industry are

  • Advanced Instruments, LLC.
  • AGC Biologics
  • Catalent
  • Corning Inc.
  • Cyagen
  • Cytiva
  • Eurofins
  • FUJIFILM Diosynth Biotechnologies
  • GenScript Biotech Corporation
  • Horizon Discovery
  • Imgenex
  • Lonza
  • NAEJA RGM Pharmaceuticals
  • Novartis
  • Premas Biotech
  • Probiogen
  • PromoCell
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Sartorius AG
  • Selexis SA
  • Vista Biologics
  • Syngene International Limited
  • Thermo Fisher Scientific Inc.
  • Vista Biologicals
  • WuXi AppTec 

These market players are implementing various growth strategies, partnerships, launches, mergers, and acquisitions to enhance product capabilities to sustain market competition in the cell line development industry.

Some of the recent industry developments:

  • In March 2021, Selexis SA and SpyBiotech signed a license agreement to advance human cytomegalovirus (HCMV) vaccine program. SpyBiotech will use Selexis’s SUREtechnology platform to produce stable, high yielding cell lines for human clinical trials.   This helped in advancement of both the companies thus increasing its sales.
  • In July 2020, Merck completed its acquisition of RESOLUTION Spectra Systems, a French-based company in bioprocess analytical monitoring. This acquisition helped Merck in delivering real-time monitoring for intensified and continuous bioprocessing.

The cell line development market report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue in USD from 2022 to 2028, for the following segments:

Click here to Buy Section of this Report

By Product

  • Reagents & Media
  • Equipment
    • Incubator
    • Centrifuge
    • Bioreactor
    • Storage equipment
    • Microscope
    • Electroporators
    • FACS
    • Others
  • Accessories & Consumables

By Source

  • Mammalian
  • Non-mammalian
    • Insects
    • Amphibians

By Cell Line

  • Recombinant
  • Hybridomas
  • Continuous cell line
  • Primary cell line

By Application

  • Bioproduction
  • Drug discovery
  • Toxicity testing
  • Tissue engineering
  • Research

The above information is provided for the following regions and countries:

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Russia
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Cell line development market is slated to surpass USD 11.6 billion by 2028 and could grow at a CAGR of about 10.1% from 2022 to 2028 driven by growing vaccine production and constant technological developments.

In 2021, the reagents and media segment captured around 53% of the overall market share and will grow as the product contains supplements and sera that support cell survival, biological function, and proliferation.

The overall market revenue from recombinant cell lines could grow at a CAGR of more than 9.5% over 2022-2028 driven by increasing investment in R&D activities to develop new products and constant technological advancements.

Cell line development market share from bioproduction application was recorded at around USD 2.7 billion in 2021 and will grow owing to soaring expenditure on R&D to produce various biological substances like vaccines, antibiotics, and more.

North America held more than 34% of the global cell line development market share in 2021 owing to novel drug discoveries further encouraging the adoption of different and unique bioproduction procedures.

Cell Line Development Market Scope

Buy Now

Immediate Delivery Available

Premium Report Details

  • Base Year: 2021
  • Companies covered: 26
  • Tables & Figures: 351
  • Countries covered: 17
  • Pages: 238
 Download Free Sample